{
    "id": 23241,
    "fullName": "INSR positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "INSR positive indicates the presence of the INSR gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3643,
        "geneSymbol": "INSR",
        "terms": [
            "INSR",
            "CD220",
            "HHF5"
        ]
    },
    "variant": "positive",
    "createDate": "06/15/2016",
    "updateDate": "07/17/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9237,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) did not inhibit growth of rat hepatocellular carcinoma cells with activated Insr signaling via insulin stimulation in culture (PMID: 27780853).",
            "molecularProfile": {
                "id": 23918,
                "profileName": "INSR positive"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7044,
                    "pubMedId": 27780853,
                    "title": "The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6871,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tarceva (erlotinib) and Linsitinib (OSI-906) combination treatment decreased Igf1r and Insr phosphorylation, resulted in a disease control rate of 51% (38/75), and partial response in 7% (5/75) of patients with advanced solid tumors, including a rectal cancer patient who remained on study for 36 weeks (PMID: 26831715).",
            "molecularProfile": {
                "id": 23919,
                "profileName": "IGF1R pos INSR pos"
            },
            "therapy": {
                "id": 4041,
                "therapyName": "Erlotinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5935,
                    "pubMedId": 26831715,
                    "title": "Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831715"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6872,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tarceva (erlotinib) and Linsitinib (OSI-906) combination treatment decreased Igf1r and Insr phosphorylation, resulted in a disease control rate of 51% (38/75), and partial response in 7% (5/75) of patients with advanced solid tumors, including three non-small cell lung carcinoma patients who remained on study for 16, 72, 36 weeks, respectively (PMID: 26831715).",
            "molecularProfile": {
                "id": 23919,
                "profileName": "IGF1R pos INSR pos"
            },
            "therapy": {
                "id": 4041,
                "therapyName": "Erlotinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5935,
                    "pubMedId": 26831715,
                    "title": "Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831715"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6869,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tarceva (erlotinib) and Linsitinib (OSI-906) combination treatment decreased Igf1r and Insr phosphorylation, resulted in partial response in 7% (5/75), and a disease control rate of 51% (38/75) in patients with advanced solid tumors (PMID: 26831715).",
            "molecularProfile": {
                "id": 23919,
                "profileName": "IGF1R pos INSR pos"
            },
            "therapy": {
                "id": 4041,
                "therapyName": "Erlotinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5935,
                    "pubMedId": 26831715,
                    "title": "Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831715"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6870,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tarceva (erlotinib) and Linsitinib (OSI-906) combination treatment decreased Igf1r and Insr phosphorylation, resulted in a disease control rate of 51% (38/75), and partial response in 7% (5/75) of patients with advanced solid tumors, including a spinal chordoma patient who remained on study for more than 268 weeks (PMID: 26831715).",
            "molecularProfile": {
                "id": 23919,
                "profileName": "IGF1R pos INSR pos"
            },
            "therapy": {
                "id": 4041,
                "therapyName": "Erlotinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4153,
                "name": "spinal chordoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5935,
                    "pubMedId": 26831715,
                    "title": "Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831715"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23918,
            "profileName": "INSR positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23919,
            "profileName": "IGF1R pos INSR pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}